Drug Trial Radar · NCT02447536
Trial of Two Strains of BCG
Last checked: Nov 19, 2026Latest source record: Dec 16, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12,006
Actual
Start
Dec 8, 2014
Primary completion
Nov 24, 2017
Study completion May 1, 2018
Sponsor
- Lead sponsor
- Bandim Health ProjectAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Statens Serum Institut
- First posted
- May 19, 2015
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The investigators aim to conduct a randomised controlled trial comparing two Bacille Calmette-Guérin (BCG) strains currently used in Guinea-Bissau, the Danish and the Russian, in terms of prevention of neonatal and early life morbidity and mortality, immune responses and adverse events related to BCG vaccination. The primary outcome will be hospital admissions within 6 weeks of age.
Conditions
- Morbidity
- Bacille Calmette-Guérin
Interventions
BCG-Denmark 1331 (Statens Serum Institute)Biological
See above
BCG-Russia-I (Serum Institute of India)Biological
See above
Primary outcomes
What the sponsor says the trial is designed to measure.
- Hospital admissionTime frame: 6 weeks after birth
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Bandim Health Project, Apartado 861
Bissau, Guinea-Bissau
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.